Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pritelivir · AIC-316, AIC-090093

Small molecule · Inhibitor of herpes simplex virus helicase-primase complex · developed by AiCuris Anti-infective Cures

Phase 3 Most advanced trial (none active)

2 Registered trials

What is Pritelivir?

Pritelivir is a thiazolylamide small-molecule inhibitor of the herpes simplex virus helicase-primase complex. It prevents viral DNA replication by blocking helicase and primase catalytic cycling, and does not require HSV thymidine kinase activation. It is studied in genital herpes and HSV infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AIC-316, AIC-090093
Drug type: Small molecule
Targets: herpes simplex virus helicase-primase complex
Mechanism: Inhibitor of herpes simplex virus helicase-primase complex
Pathways: viral DNA replication
Therapy area: Infectious disease
Developer: AiCuris Anti-infective Cures AG
In trials of: MEDP
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 07HQ1TJ4JE

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03073967	Phase 3	HSV Infection	Completed	MEDP
NCT01658826	Phase 2	Genital Herpes	Terminated	MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Genital HerpesHSV Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z